Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma

BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway have clinical activity in hepatocellular carcinoma (HCC), but only a subset of patients respond to these therapies, highlighting a need for novel bi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Ho, Won Jin, Danilova, Ludmila, Lim, Su Jin, Verma, Rohan, Xavier, Stephanie, Leatherman, James M, Sztein, Marcelo B, Fertig, Elana J, Wang, Hao, Jaffee, Elizabeth, Yarchoan, Mark
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Clinical/Translational Cancer Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7204805/
https://ncbi.nlm.nih.gov/pubmed/32303615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000394
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia